Shilpa Medicare DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.88×	0.82×	0.63×	0.54×	0.94×
	0.96×	0.94×	0.61×	0.43×	−5.08×
	21.0%	20.5%	15.9%	11.9%	0.6%
	0.44×	0.44×	0.40×	0.38×	0.36×
	1.43×	1.43×	1.40×	1.72×	1.64×
	11.1%	9.9%	3.4%	1.8%	−1.8%
	9.8%	9.8%	3.8%	1.8%	−1.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SHILPAMED₹935.60

Shilpa Medicare Ltd.

· Pharma & Health

₹ CrorePeersNATCOPHARM SPARC STAR RUBICON SUPRIYA THYROCARE VIYASH PARKHOSPSMcap ₹18,300 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.94	0.54	0.63	0.82	0.88
Interest Burden (Pretax/EBIT) ×	-5.08	0.43	0.61	0.94	0.96
EBIT Margin %	0.65	11.86	15.86	20.47	20.95
Asset Turnover ×	0.36	0.38	0.40	0.44	0.44
Financial Leverage (Assets/Equity) ×	1.64	1.72	1.40	1.43	1.43
ROE (5-step product, year-end total equity) %	-1.82	1.81	3.41	9.95	11.12
ROE (owners' profit / average owners' equity) %	-1.80	1.77	3.75	9.80	9.80

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.